PRA Health Sciences

PRA Health Sciences

Dedicated to the future of clinical development and to every life it saves. Learn more

Financials

Estimates*

Edit
Revenues, earnings & profits over time
USD201720182019202020212022
Revenues2.3b2.9b3.1b3.2b3.6b4.0b
% growth-27 %7 %4 %15 %9 %
EBITDA339m429m482m416m615m690m
% EBITDA margin15 %15 %16 %13 %17 %17 %
Profit86.0m154m243m197m248m310m
% profit margin4 %5 %8 %6 %7 %8 %
EV / revenue2.5x2.1x2.7x2.8x--
EV / EBITDA17.0x13.9x17.1x21.7x--
  • Edit
DateInvestorsAmountRound
-

N/A

-
N/A

N/A

IPO
N/A

$3.0k

Grant

$12.0b

Valuation: $12.0b

3.8x EV/LTM Revenues

28.8x EV/LTM EBITDA

Acquisition
Total FundingCAD4.1k

Recent News about PRA Health Sciences

Edit
More about PRA Health Sciencesinfo icon
Edit

PRA Health Sciences is a global healthcare intelligence partner specializing in clinical trial management and drug development. The company serves pharmaceutical and biotechnology firms, providing end-to-end support for clinical trials, from initial concept to final approval. Operating in the highly regulated healthcare market, PRA leverages its extensive expertise in recruitment, retention, and compliance to ensure rapid and efficient trial enrollment. The business model revolves around offering specialized services through its Centers of Expertise, which focus on areas such as vaccine research, pediatric clinical development, and immuno-oncology. PRA generates revenue by partnering with clients to design, manage, and execute clinical trials, thereby accelerating the path to market for new treatments. The company is consistently ranked among the top Contract Research Organizations (CROs) and is known for its people-first culture, emphasizing value, respect, and support for its employees.

Keywords: clinical trials, drug development, healthcare intelligence, pharmaceutical, biotechnology, recruitment, compliance, immuno-oncology, pediatric trials, global infrastructure.

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.
Investments analysisEdit

Investments by PRA Health Sciences

Edit
Parallel 6
ACQUISITION by PRA Health Sciences Aug 2017
Nextrials
ACQUISITION by PRA Health Sciences Mar 2016
ReSearch Pharmaceutical Services
ACQUISITION by PRA Health Sciences Sep 2013
ClinCare Consulting
ACQUISITION by PRA Health Sciences Dec 2003
ClinStar
ACQUISITION by PRA Health Sciences Mar 2013
Symphony Health Solutions
ACQUISITION by PRA Health Sciences Aug 2017
Regulatory/Clinical Consultants
ACQUISITION by PRA Health Sciences Jun 2005
CRI Lifetree
ACQUISITION by PRA Health Sciences Nov 2013
GMG BioBusiness
ACQUISITION by PRA Health Sciences Jun 2005
Value Health Solutions
ACQUISITION by PRA Health Sciences Aug 2015
View 1 more